Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Nuvectis Pharma Inc (NVCT)

Nuvectis Pharma Inc (NVCT)
9.40 x 1 10.84 x 3
Post-market by (Cboe BZX)
10.41 +1.14 (+12.30%) 04/23/25 [NASDAQ]
9.40 x 1 10.84 x 3
Post-market 10.40 -0.01 (-0.10%) 16:08 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
9.10
Day High
10.45
Open 9.72
Previous Close 9.27 9.27
Volume 156,800 156,800
Avg Vol 117,150 117,150
Stochastic %K 63.73% 63.73%
Weighted Alpha +131.78 +131.78
5-Day Change +0.88 (+9.23%) +0.88 (+9.23%)
52-Week Range 4.44 - 11.80 4.44 - 11.80
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 216,844
  • Shares Outstanding, K 23,392
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,000 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta -0.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 16.59

Options Overview Details

View History
  • Implied Volatility 179.18% ( +22.96%)
  • Historical Volatility 108.83%
  • IV Percentile 44%
  • IV Rank 16.41%
  • IV High 500.86% on 12/20/24
  • IV Low 116.03% on 02/21/25
  • Put/Call Vol Ratio 1.43
  • Today's Volume 17
  • Volume Avg (30-Day) 225
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 1,783
  • Open Int (30-Day) 3,019

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.30
  • Number of Estimates 2
  • High Estimate -0.28
  • Low Estimate -0.31
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.61 +36.78%
on 04/07/25
Period Open: 10.20
10.71 -2.81%
on 03/31/25
+0.21 (+2.06%)
since 03/21/25
3-Month
5.81 +79.17%
on 02/05/25
Period Open: 6.42
10.71 -2.81%
on 03/31/25
+3.99 (+62.15%)
since 01/23/25
52-Week
4.44 +134.46%
on 12/23/24
Period Open: 6.59
11.80 -11.78%
on 11/12/24
+3.82 (+57.97%)
since 04/23/24

Most Recent Stories

More News
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

NVCT : 10.41 (+12.30%)
Nuvectis Pharma to Participate in the 37th Annual Roth Conference

NVCT : 10.41 (+12.30%)
Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

NVCT : 10.41 (+12.30%)
Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights

NVCT : 10.41 (+12.30%)
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option

NVCT : 10.41 (+12.30%)
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

NVCT : 10.41 (+12.30%)
Nuvectis Pharma Announces Proposed Public Offering of Common Stock

NVCT : 10.41 (+12.30%)
Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – The American Cancer Society has unveiled its Advances in Oncology – 2024 Research Highlights report,...

ONCY : 0.5666 (-5.57%)
PSNL : 3.68 (+7.92%)
ALXO : 0.5800 (-2.18%)
ONC.TO : 0.79 (-5.95%)
NVCT : 10.41 (+12.30%)
TEM : 49.55 (+14.62%)
Insider Purchase: 10% owner at $NVCT (NVCT) Buys 17,000 Shares

Marlio Charles Mosseri, a 10% owner of $NVCT ($NVCT), bought 17,000 shares of the company on 12-13-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

NVCT : 10.41 (+12.30%)
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium

NVCT : 10.41 (+12.30%)

Business Summary

Nuvectis Pharma Inc. is a biopharmaceutical company. It focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. Nuvectis Pharma Inc. is based in Fort Lee, NJ.

See More

Key Turning Points

3rd Resistance Point 12.22
2nd Resistance Point 11.33
1st Resistance Point 10.87
Last Price 10.41
1st Support Level 9.53
2nd Support Level 8.64
3rd Support Level 8.18

See More

52-Week High 11.80
Last Price 10.41
Fibonacci 61.8% 8.99
Fibonacci 50% 8.12
Fibonacci 38.2% 7.25
52-Week Low 4.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective